|
|
AllVascular Pty Ltd
|
| |
|
AllVascular is an innovative company focused on the research, development, and commercialisation of novel medical devices and treatments in the field of vascular surgery. Our current projects include bench-top basic science work, in vivo animal trials, and human clinical trials, with a clinical focus extending from arterial and venous disease, to oncology and chemotherapy delivery. AllVascular has several clinical trials currently underway in Australia and Europe.
AllVascular currently has distributors for the Venocuff II® appointed in Greece, Austria, Germany, Switzerland, and the UK. We are interested in identifying suitable distributors in Spain, Italy, France, and Benelux. We are also interested in joint-venture or partnerships with companies focused on vascular and cardiac surgery or treatments.
Venocuff II® is a novel treatment for the repair of incompetent venous valves associated with varicose veins. The Venocuff II® has been used for 20 years in Australia, with over 5,000 implants performed. The Venocuff II® has significantly better long-term outcomes than ablative techniques. Products currently in clinical trials are the Endovenous Valve Transfer Stent (EVTS) for the treatment of deep venous disease, and an arterial access device and novel treatment for peripheral arterial disease.
Our products major competitive advantages are due to the fact that they are invented and developed by surgeons. This means that the products are suit end-user want and needs. The Venocuff II® for example, is a reparative device for varicose veins with an exceptional long-term outcome. The treatment is fast, simple, cheap, and highly effective – all desired by the treating surgeon, patient, and hospital.
www.allvascular.com
 
| |
|
|
|
|
|
|
|
|
|
|